Cargando…

Single Dose IV Peramivir is Safe and Effective in the Treatment of Pediatric Influenza

BACKGROUND: Peramivir (PVR) is a potent neuraminidase inhibitor with in vitro activity against all influenza virus subtypes. Previous studies demonstrated the efficacy and safety of PVR as a single dose intravenous (IV) treatment for acute uncomplicated influenza in adults. METHODS: A phase 3 study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vanchiere, John, Plunkett, Stephanie, Annamalai, Rajasekaran, Julien, Katie, Peterson, James, Goisse, Marcy, Christensen, Shane, Mehta, Priyesh, Coleman, Stephen, Munoz, Flor, Flynt, Amy, Dobo, Sylvia, Nagy, Eniko, Kargl, Deborah, Mathis, Amanda, Collis, Phil, Sheridan, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630974/ http://dx.doi.org/10.1093/ofid/ofx163.1861

Ejemplares similares

827 The efficacy of single dose peramivir in acute uncomplicated influenza: an integrated subject-level meta-analysis
por: Whitley, Richard, et al.
Publicado: (2014)

Peramivir for influenza
Publicado: (2019)

Safety and efficacy of peramivir for influenza treatment
por: Hata, Atsuko, et al.
Publicado: (2014)

Clinical Effectiveness and Safety of Peramivir for Influenza Infection: Safe and Effective Antiviral Treatment
por: Lee, Jin Seo
Publicado: (2018)

Oseltamivir/peramivir: Lack of efficacy: case report
Publicado: (2020)

Peramivir and laninamivir susceptibility of circulating influenza A and B viruses
por: Leang, Sook-Kwan, et al.
Publicado: (2014)

Peramivir injection in the treatment of acute influenza: a review of the literature
por: Wester, Ashley, et al.
Publicado: (2016)

PEPT1-mediated prodrug strategy for oral delivery of peramivir
por: Sun, Yongbing, et al.
Publicado: (2018)

Clinical Effectiveness of Peramivir in Comparison with Other Neuraminidase Inhibitors in Pediatric Influenza Patients
por: Hikita, Toshiyuki, et al.
Publicado: (2012)

Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections
por: Alame, Malak M., et al.
Publicado: (2016)

A Case of Influenza Associated Fulminant Myocarditis Successfully Treated with Intravenous Peramivir
por: Baik, Seung Hee, et al.
Publicado: (2015)

Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection
por: Pascua, Philippe Noriel Q., et al.
Publicado: (2017)

Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients
por: Lee, Jin Seo, et al.
Publicado: (2020)

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
por: Twabela, Augustin, et al.
Publicado: (2020)

Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects
por: Zhang, Chen-xi, et al.
Publicado: (2022)

Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial
por: Ohsawa, Isao, et al.
Publicado: (2020)

Use of Intravenous Peramivir in a Critically Ill Toddler With Influenza A Infection and Cardiac Involvement
por: Chaudhary, Manu, et al.
Publicado: (2015)

Detection of Peramivir and Laninamivir, New Anti-Influenza Drugs, in Sewage Effluent and River Waters in Japan
por: Azuma, Takashi, et al.
Publicado: (2015)

Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis
por: Lee, Jonghoo, et al.
Publicado: (2017)

A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment
por: Chen, Jui-Yi, et al.
Publicado: (2020)

Use of Intravenous Peramivir for Treatment of Severe Influenza A(H1N1)pdm09
por: Louie, Janice K., et al.
Publicado: (2012)

Clinical Experience in Adults and Children Treated with Intravenous Peramivir for 2009 Influenza A (H1N1) Under an Emergency IND Program in the United States
por: Hernandez, Jaime E., et al.
Publicado: (2011)

A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia
por: Wang, Jin-na, et al.
Publicado: (2019)

Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model
por: Farooqui, Amber, et al.
Publicado: (2015)

Safety and Effectiveness of Peramivir in Korean Adult Influenza Patients: Prospective Observational Study Based on Post-Marketing Surveillance Data
por: Choi, Won Suk, et al.
Publicado: (2018)

Combination Effects of Peramivir and Favipiravir against Oseltamivir-Resistant 2009 Pandemic Influenza A(H1N1) Infection in Mice
por: Park, Sehee, et al.
Publicado: (2014)

Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents
por: Seki, Masafumi, et al.
Publicado: (2019)

Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study
por: Chen, Hong-Dou, et al.
Publicado: (2020)

Impact of the 2009/2010 influenza A (H1N1) pandemic on trends in influenza hospitalization, diagnostic testing, and treatment
por: Hernandez, Jaime E., et al.
Publicado: (2011)

Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study
por: Zhang, Yan, et al.
Publicado: (2016)

Efficacy of delayed treatment of China-made Peramivir with repeated intravenous injections in a mouse influenza model: from clinical experience to basal experiment
por: Li, Zhengtu, et al.
Publicado: (2016)

Intravenous peramivir vs oral oseltamivir in high‐risk emergency department patients with influenza: Results from a pilot randomized controlled study
por: Hsieh, Yu‐Hsiang, et al.
Publicado: (2020)

Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study
por: Nakamura, Shigeki, et al.
Publicado: (2017)

Intermolecular Mechanism and Dynamic Investigation of Avian Influenza H7N9 Virus’ Susceptibility to E119V-Substituted Peramivir–Neuraminidase Complex
por: Mtambo, Sphamandla E., et al.
Publicado: (2022)

Impact of the R292K Mutation on Influenza A (H7N9) Virus Resistance towards Peramivir: A Molecular Dynamics Perspective
por: Mtambo, Sphamandla E., et al.
Publicado: (2022)

P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS
por: Kulasekararaj, A., et al.
Publicado: (2022)

Independent-Trajectories Thermodynamic-Integration Free-Energy Changes for Biomolecular Systems: Determinants of H5N1 Avian Influenza Virus Neuraminidase Inhibition by Peramivir
por: Lawrenz, Morgan, et al.
Publicado: (2009)

Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study
por: Kato, Motokazu, et al.
Publicado: (2020)

Improvement of respiratory symptoms and health‐related quality of life with peramivir in influenza patients with chronic respiratory disease: Additional outcomes of a randomized, open‐label study
por: Kato, Motokazu, et al.
Publicado: (2021)

In Silico Studies Reveal Peramivir and Zanamivir as an Optimal Drug Treatment Even If H7N9 Avian Type Influenza Virus Acquires Further Resistance
por: Sarukhanyan, Edita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ovna67c13c2guj5nc3amc36pf9